CRS webinar presented by the CRS Satellite Meeting Committee
Original broadcast date: January 30, 2015
Access Webinar On-Demand (Only those who registered for the webinar will be able to log-in to access the on-demand version of this webinar)
An enhanced permeability and retention (EPR) effect is a unique tumor vascular phenomenon that allows for selective concentration of nanosized agents in tumor tissues. Since it was first described in the 1980’s by Dr. Hiroshi Maeda, many investigators have adapted this concept in designing targeted anticancer drugs aimed at higher anticancer activity and lower toxicity. EPR effect served as the bridge through which nanotechnology found appropriate application in cancer treatment. However, to date only nine anticancer nanomedicines have crossed the “translational valley of death” to reach the clinic.
In this webinar, we will review our knowledge of anticancer nanomedicine and lessons learned over the last 30 years. We’ll also discuss how we can further improve tumor targeting by exploiting the tumor microenvironment. Our speakers will evaluate the value of receptor mediated targeting of nano-constructs as a beneficial strategy in cancer treatment.
Two distinguished speakers will contribute to this webinar -- Professor Hiroshi Maeda, who discovered and extensively studied the EPR effect and invented SMANCS, the first anticancer nanomedicine globally approved, and Professor Gert Storm, an expert in the area of targeted drug delivery and their application in preclinical and clinical settings.
Dr. Maeda , M.D., Ph.D., Professor Emeritus of Kumamoto University and Professor of Sojo University, DDS Research Center, is a world-renowned expert in macromolecular therapeutics. He was successful in creating the world first polymeric drug, SMANCS, which was approved for treatment of hepatoma in Japan in 1994. Along this line he discovered the concept of EPR (enhanced permeability and retention)-effect of macromolecular drugs, a ubiquitous mechanism which is responsible for solid-tumor selective targeting of polymeric drugs. More recently, he has developed a numbers of macromolecular/micellar drugs with very high tumor-selective accumulation. This concept is also applicable to micellar and liposomal drugs, gene-complexed nano-particles, and even oncolytic virus particles. Dr. Maeda received his Master’s Degree from the University of California at Davis, where he was a Fulbright Fellow, and his Ph.D. and M.D. from Tohoku University in Sendai, Japan. He has had more than 450 papers published in international scientific journals. He was awarded the Lifetime Achievement Award at the Royal Pharmaceutical Society of Great Britain. He also received the Princess Takamatsu Award in Cancer Research, Dr. Tomizo Yoshida Award -- the highest award from Japan Cancer Association in 2011, and other awards from various societies in USA, Germany and Japan.
Dr. Storm obtained his Ph.D. degree in the Department of Pharmaceutics at Utrecht University in The Netherlands. His research interests are in the fields of biopharmaceutics and drug targeting. He is an Honorary Professor in Biomacromolecular Drug Delivery at the University of Copenhagen; professor of Targeted Drug Delivery at Utrecht University; and professor (Targeted Therapeutics) at the MIRA institute of the University of Twente. He is author/co-author of more than 400 original articles, reviews and book chapters, in the field of advanced drug delivery/drug targeting, and theme (co-)editor of Advanced Drug Delivery Reviews. He was coordinator of an Integrated Project (FP6) on targeted nanomedicines (MediTrans) based on the collaboration of 30 european partners and funded by the EC and industry. He is program director of the program Drug Delivery embedded in the New Nano Initiative (NanoNextNL) sponsored by the dutch government and industry. He is also principal investigator of a national industry-academia partnership (HIFU-CHEM) studying the clinical application of MRI-guided high-intensity focused ultrasound (HIFU) to improve cancer chemotherapy with temperature-sensitive targeted nanomedicines. He is course director of the GUIDE/UIPS/LACDR Course on Advanced Drug Delivery & Drug Targeting, co-sponsored and accredited by EUFEPS and the GALENOS Network, and held in The Netherlands. He is on the Board of Scientific Advisors of the Controlled Release Society (CRS). He is on the Scientific Board of the spin-off company Enceladus Pharmaceuticals BV (Amsterdam). He is member of the editorial (advisory) board of a variety of scientific journals. He is on the board of the Dutch Society for Gene Therapy. He was involved in the foundation and is currently on the board of the European Society for Nanomedicine (ESNAM/CLINAM) and The Netherlands Platform for Targeted Nanomedicine (NPTN).
Moderator: Khaled Greish
Dr. Greish , M.D., Ph.D., is currently a senior lecturer in the Department of Pharmacology and Toxicology, Otago University, New Zealand. He graduated from the Faculty of Medicine, Suez Canal University, Egypt, and received his master’s degree in clinical oncology. He moved to Japan to join the lab of Professor Hiroshi Maeda, a world leader in the field of anticancer nanomedicine. They both developed an affordable platform nanotechnology miceller system for targeting anticancer drugs specifically to solid tumours. Dr. Greish moved to the United States to join the department of pharmaceutics and pharmaceutical chemistry department, University of Utah, as Research Assistant Professor. Dr. Greish's areas of interest span the formulation and characterization of different advanced drug delivery systems, anticancer drug discovery/development, tumour vascular biology and animal tumour models. His contribution to the field of anticancer drug delivery research was recognized by the Controlled Release Society (CRS), by awarding him the CRS Postdoctoral Achievement award and by electing him as to the CRC College of Fellows.
Registration has closed.